Active Filter(s):
Details:
Gazyva (obinutuzumab), is a glycoengineered type II anti-CD20 monoclonal antibody designed to bind to CD20, a protein expressed on certain B cells, but not on stem cells or plasma cells.
Lead Product(s): Obinutuzumab,Chlorambucil
Therapeutic Area: Oncology Product Name: Gazyva
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Nippon Shinyaku
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2022